Alto Neuroscience Raises $100M in Public Offering to Fund Phase 3 Trial and Extend Cash Runway

summarizeSummary

Alto Neuroscience secured $100 million through a public offering, which will fund the acceleration of its ALTO-207 Phase 3 clinical trial and extend its cash runway through 2030.

check_boxKey Events · Financing and Capital Events · ANRO

• Public Offering Completed

  Alto Neuroscience offered 3,776,436 shares of common stock at $26.48 per share, raising gross proceeds of $100 million and net proceeds of approximately $93.9 million.

• Strategic Use of Proceeds

  The net proceeds will be used to accelerate and expand the clinical development of ALTO-207, including an additional planned Phase 3 trial for treatment-resistant depression, and for general working capital purposes.

• Extended Cash Runway

  This financing, combined with existing cash, is expected to extend the company's cash runway through 2030, a significant improvement from the previously reported 2029 runway.

• Share Dilution

  The offering results in approximately 10.77% dilution to existing shareholders, increasing total shares outstanding to 38,829,167.

auto_awesomeAnalysis · ANRO · Life Sciences

Alto Neuroscience has successfully completed a public offering, raising approximately $93.9 million in net proceeds. This substantial capital infusion, representing over 10% of the company's market capitalization, is critical for a clinical-stage biopharmaceutical company. The funds are specifically earmarked to accelerate and expand the clinical development of ALTO-207, including a planned Phase 3 trial for treatment-resistant depression, and for general working capital. This financing extends the company's cash runway through 2030, providing crucial stability for its pipeline development. While the offering is dilutive to existing shareholders, the ability to raise significant capital at a price near the stock's 52-week high demonstrates market confidence and secures the necessary resources for advancing key clinical programs.